Welcome to our dedicated page for OMEROS SEC filings (Ticker: OMER), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on OMEROS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into OMEROS's regulatory disclosures and financial reporting.
For OMEROS CORP (OMER), VP and General Counsel Peter B. Cancelmo reported two exercise-and-sale transactions. On August 28 and August 31, 2026, he exercised stock options for a total of 50,000 shares of common stock at an exercise price of $2.94 per share and sold all 50,000 shares in the market at weighted average prices of $18.6451 and $18.5416, respectively. The sale prices are reported as weighted averages over multiple trades within disclosed intraday price ranges.
Omeros Corporation (OMER) insider Peter Brogan Cancelmo has filed a Rule 144 notice for a proposed sale of 25,000 shares of Omeros common stock through Morgan Stanley Smith Barney. The shares relate to an exercise of options under a registered plan, with an aggregate market value listed as $463,540. Omeros common shares outstanding are reported as 72,388,316 as of the notice date. The notice also lists a prior sale of 25,000 shares for $466,127.50 within the past three months.
OMEROS CORP (OMER) received a Form 144 notice from Peter Brogan Cancelmo covering a proposed sale of up to 25,000 shares of common stock. The shares are to be sold through Morgan Stanley Smith Barney LLC, in connection with the exercise of options under a registered plan for cash, with a proposed sale date of August 28, 2026.
OMEROS CORP (OMER) director Arnold C. Hanish reported option exercises and related share sales. On August 26–27, 2026, he exercised stock options for 15,000 shares of common stock at exercise prices of $14.66 and $15.81 per share, then sold 15,000 shares in open-market transactions at weighted average prices between about $18.53 and $19.02 per share. A separate indirect holding of 12,400 shares is reported as held by the Arnold C. Hanish Living Trust, which has not sold these shares.
OMEROS CORPORATION (OMER) received a notice under Rule 144 that director Arnold C. Hanish intends to sell up to 10,000 shares of common stock. The shares relate to option exercises under a registered plan and are to be handled through Morgan Stanley Smith Barney LLC Executive Financial Services.
The filing also lists that, during the prior three months, Arnold Hanish sold 5,000 shares of OMEROS common stock for $94,132.50.
OMEROS CORP (OMER) received a Rule 144 notice from director Arnold C. Hanish covering a planned sale of 5,000 shares of Omeros common stock. The shares are to be sold through Morgan Stanley Smith Barney LLC, following an exercise of options under a registered plan, with an indicated value of $94,132.50 and a proposed sale date of 08/26/2026 on NASDAQ.
OMEROS CORP (OMER) reports that its VP, Finance & CAO, David J. Borges, exercised employee stock options and sold the resulting common shares. On August 21 and 24, 2026, he exercised options to acquire a total of 10,906 shares of common stock at exercise prices of $2.94 and $3.93 per share, then sold 10,906 shares of common stock in open-market transactions at prices of $18.95 and $19.10 per share.
The sales were made pursuant to a previously established Rule 10b5-1 trading plan adopted on February 10, 2026. The exercised options relate to grants that vest over 48 equal monthly installments starting April 1, 2022 and April 1, 2023, with expiration dates in 2032 and 2033. All transactions are reported as direct ownership; post-transaction share holdings are not specified in this filing.
OMEROS CORP (OMER) director Thomas J. Cable reported an option exercise-and-sale transaction. He exercised 15,000 Stock Options (Rights to Buy) for 15,000 shares of Common Stock at exercise prices of $2.00 and $3.93 per share, then sold 15,000 shares at a weighted average price of $18.4515 per share in multiple trades ranging from $18.23 to $18.72.
OMEROS CORP (OMER) received a notice that officer David Joseph Borges intends to sell company common stock under Rule 144. The filing covers up to 10,906 shares of common stock, to be obtained by the exercise of stock options and sold for cash, with sales referenced as occurring around 08/21/2026 through a brokerage account at Morgan Stanley Smith Barney LLC on NASDAQ.
The notice also lists a prior sale under a Rule 10b5-1 trading plan in the past three months, where 5,000 shares of common stock were sold for $84,750.00 on 08/13/2026. The remarks state that the securities to be sold were and will be received upon option exercise over the next three months, with the dates of acquisition and payment matching the exercise or sale dates.
OMEROS CORP (symbol OMER) has a notice from director Thomas Cable to sell common stock under Rule 144. The filing lists up to 15,000 shares of common stock to be sold through Morgan Stanley Smith Barney LLC, with an indicated aggregate market value of $276,772.50. The shares are to come from the exercise of options under a registered plan, in two tranches of 7,500 shares each on 08/20/2026, with cash exercise. The notice also reports that Cable sold 7,500 shares of common stock for $86,806.20 on 05/22/2026 during the prior three months.